JP7278296B2 - Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド - Google Patents

Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド Download PDF

Info

Publication number
JP7278296B2
JP7278296B2 JP2020543999A JP2020543999A JP7278296B2 JP 7278296 B2 JP7278296 B2 JP 7278296B2 JP 2020543999 A JP2020543999 A JP 2020543999A JP 2020543999 A JP2020543999 A JP 2020543999A JP 7278296 B2 JP7278296 B2 JP 7278296B2
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
csf
ligand
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514368A (ja
JP2021514368A5 (enExample
Inventor
トゥゲス、ソニア
ベッヒャー、ブルクハルト
Original Assignee
ウニヴェルズィテート チューリッヒ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by ウニヴェルズィテート チューリッヒ filed Critical ウニヴェルズィテート チューリッヒ
Publication of JP2021514368A publication Critical patent/JP2021514368A/ja
Publication of JP2021514368A5 publication Critical patent/JP2021514368A5/ja
Application granted granted Critical
Publication of JP7278296B2 publication Critical patent/JP7278296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020543999A 2018-02-22 2019-02-22 Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド Active JP7278296B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (3)

Publication Number Publication Date
JP2021514368A JP2021514368A (ja) 2021-06-10
JP2021514368A5 JP2021514368A5 (enExample) 2021-10-21
JP7278296B2 true JP7278296B2 (ja) 2023-05-19

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543999A Active JP7278296B2 (ja) 2018-02-22 2019-02-22 Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド

Country Status (11)

Country Link
US (3) US11655293B2 (enExample)
EP (1) EP3755715A1 (enExample)
JP (1) JP7278296B2 (enExample)
KR (1) KR20200123434A (enExample)
CN (1) CN111886248B (enExample)
AU (1) AU2019224550A1 (enExample)
BR (1) BR112020017253A2 (enExample)
CA (1) CA3091536A1 (enExample)
MA (1) MA51893A (enExample)
MX (2) MX2020008792A (enExample)
WO (1) WO2019162472A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12384839B2 (en) 2018-02-22 2025-08-12 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541195A (ja) 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
JP2007116947A (ja) 2005-10-26 2007-05-17 Evec Inc ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2011518857A (ja) 2008-04-29 2011-06-30 マイクロメット アーゲー 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
US20150246969A1 (en) 2012-09-20 2015-09-03 Morphosys Ag Treatment for rheumatoid arthritis
US20150376285A1 (en) 2006-03-27 2015-12-31 Medimmune Limited Antibody Molecule For Human GM-CSF Receptor Alpha
JP2016117700A (ja) 2014-12-24 2016-06-30 学校法人関西医科大学 制御性ｔ細胞分化誘導剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541195A (ja) 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
JP2007116947A (ja) 2005-10-26 2007-05-17 Evec Inc ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US20150376285A1 (en) 2006-03-27 2015-12-31 Medimmune Limited Antibody Molecule For Human GM-CSF Receptor Alpha
JP2011518857A (ja) 2008-04-29 2011-06-30 マイクロメット アーゲー 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
US20150246969A1 (en) 2012-09-20 2015-09-03 Morphosys Ag Treatment for rheumatoid arthritis
JP2016117700A (ja) 2014-12-24 2016-06-30 学校法人関西医科大学 制御性ｔ細胞分化誘導剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Trial：Study NCT02546284，2017年03月13日，https://clinicaltrials.gov/ct2/history/NCT02546284?A=10&B=10&C=merged#StudyPageTop

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12384839B2 (en) 2018-02-22 2025-08-12 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Also Published As

Publication number Publication date
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
RU2020129401A3 (enExample) 2022-03-22
US20190256587A1 (en) 2019-08-22
MA51893A (fr) 2020-12-30
KR20200123434A (ko) 2020-10-29
CN111886248B (zh) 2025-03-04
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
AU2019224550A1 (en) 2020-09-17
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
JP7257374B2 (ja) Ｔ制御性細胞の増殖または枯渇方法
Zhou et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Shin et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+ CD25+ Foxp3+ regulatory T cells
US12384839B2 (en) Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US20250197498A1 (en) Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
JP2025508129A (ja) Ｅｐｏ受容体アゴニストおよびアンタゴニスト
US20240226168A1 (en) Engineered nk cells and uses thereof
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
Li et al. Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages
EP3623382A1 (en) Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US20230338423A1 (en) Targetable immune checkpoint for immunotherapy
US20250213687A1 (en) Therapeutic t cell product
US20240131155A1 (en) T cells for use in therapy
WO2024014523A1 (en) Anti-aqp3 antibody cancer therapy
Cassano Regulatory T Cells Induce and Maintain Alloreactive CD4+ T Cell Anergy in Costimulation Blockade-Mediated Transplantation Tolerance
Reighard A natural killer cell-centric approach toward new therapeutics for autoimmune disease
Cabrera-Pérez Examining helper T-cell recovery after sepsis
BR122020024818B1 (pt) Molécula de ácido nucleico isolada, molécula polipeptídica isolada, molécula de car isolada, domínio de ligação anti-egfrviii, vetor, método para produção de uma célula e para gerar uma população de células modificadas por rna, e uso de uma quantidade eficaz de uma célula que expressa uma molécula de car

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230509

R150 Certificate of patent or registration of utility model

Ref document number: 7278296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150